TY - JOUR T1 - Formamidinodoxorubicins Are more Potent than Doxorubicin as Apoptosis Inducers in Human Breast Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 1935 LP - 1940 VL - 35 IS - 4 AU - AGNIESZKA MARCZAK AU - MARTA DENEL-BOBROWSKA AU - MAŁGORZATA ŁUKAWSKA AU - IRENA OSZCZAPOWICZ Y1 - 2015/04/01 UR - http://ar.iiarjournals.org/content/35/4/1935.abstract N2 - Background/Aim: The ability of five formamidinodoxorubicins to induce apoptosis of MCF-7 breast cancer cells was tested. All these compounds were modified at C-3’ and contain a formamidine group (−N=CH–NRR), with the rest of the cyclic secondary amine (HNRR) of a gradually increasing ring size. Materials and Methods: Cytotoxicity was assessed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. To analyze apoptosis, double staining using fluorescence probes Hoechst 33258/propidium iodide (PI) and annexin V- Fluorescein isothiocyanate/PI was carried-out. Additionally, the TdT-mediated dUTP nick-end labelling test and activity of caspase 3 were determined. Results: The four tested derivatives displayed a significant increase in antiproliferative activity in comparison to doxorubicin. All of the tested derivatives induced caspase-dependent apoptosis of MCF-7 cells. Conclusion: DOX-F MOR and DOX-F PAZ analogs are more potent apoptosis inducers than doxorubicin. ER -